

A high-growth, disruptive company with validated soft tissue regeneration products. Supported by innovative digital platforms to address global health issues. Patented fish skin technologies originating from Isafjordur, 20 miles south of the Arctic Circle.

kerecis[®]

Who We Are

From the town of Isafjordur in northwest Iceland, Kerecis develops, manufactures, and sells patented intact fish skin products for soft tissue regeneration that have received regulatory clearance in the United States, Europe, and other regions. We provide our customers with innovative digital tools for managing their business that include the use of artificial intelligence (AI) to support insurance billing.


We have regional headquarters in the United States, Iceland, and Germany.

Our Mission

To become the world leader in tissue regeneration by sustainably harnessing nature's own remedies

Our Vision

To extend life by supporting the body's own ability to regenerate



The Science Behind Kerecis' Fish Skin Technology

Fish skin is homologous to human skin. When applied to the human body, it provides the ideal environment for the body to recruit its own cells in the regeneration process, remaining in place and ultimately converting into living tissue. The fish skin is rich in healthy fatty acids, important proteins, and is non-allergenic.

Because there is no known viral or prion transfer risk between North Atlantic cod and humans, the Kerecis fish skin is only gently processed and retains its similarity to human tissue. The gentle processing preserves the skin's original three-dimensional structure, with its inherent natural strength, complexity, and molecules all maintained.

Kerecis has a proven scientific track record, with more than 50 studies completed to date using our technology. These include three large, double-blind, comparative, randomized control trials in which fish skin treatment was demonstrated to be more efficacious than mammalian-based treatments.

Supporting Evidence

Read the Science Behind the Products




As of 2024, there are over 65 Peer Reviewed Publications supporting the use of Kerecis



Digitalization

We provide our customers with tools to manage their business with Kerecis in real time. The Kerecis Current application and artificial intelligence (AI) enable secure submission and tracking of insurance verification and billing support cases, provide access to essential clinical literature, and allow orders to be placed. This way, less time is spent on the phone, faxes, or legacy systems. Likewise our Workspace application gives the sales force real-time access to the company's various tools, increasing productivity.



*Product release pending

Our Products

Kerecis currently operates and has developed product portfolios based on approved indications in the surgical (SurgiClose/SurgiBind), wound (MariGen), and burn (GraftGuide) segments. Kerecis products are classified as medical devices.

Products are available in sheets that are either solid, fenestrated, or meshed. Micro is intact fish skin that is fragmented, and upon rehydration, can be inserted or poured directly into wounds that are complex or irregular.

Kerecis is actively working on expanding its portfolio within the segments it already operates in. New product development projects are underway which not only focus on addressing existing segments, but also new segments, such as oral surgery and breast reconstruction.

Our Commitment to Sustainability

Net Zero Emission

Kerecis is tracking its greenhouse gas emission and is working towards a future goal of Net Zero emission.



Sustainability at Our Core

We are committed to continuous improvement of the sustainability of our value chain and product design.



Promoting Ocean Conservation

Kerecis is an active champion of the responsible use of Arctic and marine resources and ocean conservation.



Experienced Management Team and Scientific Advisory Board

The Kerecis management team is comprised of seasoned executives with proven track records in building successful medical device businesses, clinical development, and the protection of intellectual property. Kerecis founder and CEO, Fertram Sigurjonsson, has held multiple medical and entrepreneurial positions, including one at Ossur, the world's largest noninvasive orthopedic company. The company's scientific advisory board is comprised of respected key opinion leaders, including medical doctors, and university professors.



Fertram Sigurjonsson
Founder & CEO
gfs@kerecis.com

“ I believe that Kerecis can help millions of people overcome grave challenges to their health. The need for new therapeutic options is enormous. Multiple clinical trials have proven the efficacy of our products, which are environmentally friendly, harvested from a sustainable stock of wild cod, and is processed with renewable Icelandic energy. This is our contribution to a healthier world population.